|
 |
Ken Tanaka is Vice President, Research and Development, of Paratek
Pharmaceuticals. Dr. Tanaka has over 20 years of experience in
research and development in the pharmaceutical industry at both
large and small pharmaceutical companies. In 1981, he joined E.
R. Squibb & Sons, Inc. as a scientist in its monobactam and NCE
programs. Recruited by Schwarz Pharma in 1987 to lead their US
clinical development effort, Dr. Tanaka then moved to Abbott
Laboratories as head of microbiology in 1991. At Abbott, he was
involved in the macrolide, quinolone, and NCE discovery programs,
as well as the development and marketing support processes for
clarithromycin, temofloxacin, and ABT-773. In 1997, he joined
PathoGenesis Corp., as its Senior Director of Anti-infective
Drug Evaluation, supervising development efforts and marketing
of aerosolized tobramycin. He received his Ph.D. in Microbiology
from Northwestern University in 1978, and did his postdoctoral
training in clinical microbiology at the University of Washington,
Seattle, Washington.
|
